InnoCare Pharma and ArriVent Biopharma announced a clinical development collaboration to evaluate the combination of InnoCare’s novel SHP2 allosteric inhibitor, ICP-189, with ArriVent’s furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor.
